Scarica l'app Stockscreener
3.80
3.80%
-0.15
Dopo l'orario di chiusura:
3.81
0.01
+0.26%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MNKD Giù?
Forum
Previsione
Frazionamento azionario
Mannkind Corp Borsa (MNKD) Ultime notizie
Truist Financial Maintains MannKind(MNKD.US) With Buy Rating, Announces Target Price $6 - Moomoo
Delaware Court Ruling Boosts MannKind (MNKD) Outlook Amid Liquid - GuruFocus
Form 4 MannKind Corp For: 28 September By Investing.com - Investing.com South Africa
Director Steven Binder Sells 39,051 Shares of MannKind Corp (MNK - GuruFocus
Steven Binder sells $128,477 of MannKind (MNKD) stock - Investing.com
MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ - Stocktwits
Form 144 MannKind Corporation For: 25 September By Investing.com - Investing.com Canada
Shares valued at $128,478 are proposed for sale by MannKind (MNKD) director Steven Binder. - Stock Titan
MNKD Stock Heads For Strongest Month In Over Three Years As FDA Catalyst Draws Closer - Stocktwits
MNKD Stock Price, Quote & Chart - ChartMill
MannKind Corporation (MNKD) Options ChainYahoo Finance - Yahoo! Finance Canada
Mannkind Stock Price Forecast. Should You Buy MNKD? - StockInvest.us
MannKind (MNKD) Bets On Inhaled Weight Loss Amid Widening Losses - finance.yahoo.com
MannKind at H.C. Wainwright conference: new launches lift outlook - Investing.com
MannKind director Steven Binder sells $127,855 in company stock By Investing.com - Investing.com South Africa
MannKind director Steven Binder sells $127,855 in company stock - Investing.com
MNKD Stock Jumps On Receiving FDA Approval For Afrezza To Treat Diabetes In Children - Stocktwits
Cantor Fitzgerald reiterates Overweight on MannKind stock at $8 By Investing.com - Investing.com Nigeria
Cantor Fitzgerald reiterates Overweight rating on MannKind stock By Investing.com - Investing.com Nigeria
Cantor Fitzgerald reiterates Overweight rating on MannKind stock - investing.com
MNKD Reiterates by Cantor Fitzgerald -- Price Target Maintained at $6.50 - GuruFocus
MannKind (NASDAQ: MNKD) director lines up more stock sales under trading plan - Stock Titan
CT drugmaker partners on development of inhaled weight-loss treatment - Hartford Business Journal
MannKind inks obesity deal with Rose Pharma - thepharmaletter.com
Breathing In GLP-1: MannKind Partners With Rose Pharma for Inhaled Weight Management Molecule - Benzinga
MannKind signs global GLP-1 inhalation collaboration deal - grafa.com
MannKind Expands Into Weight Loss With Rose Pharma Deal – Here’s What Investors Are Watching - Yahoo Finance
MNKD Looks 44.2% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
MNKD Looks 44.2% Undervalued on GF Value™ Amid Speculative Growt - GuruFocus
MannKind partners with Rose Pharma on inhaled GLP-1 therapy By Investing.com - Investing.com India
MannKind partners with Rose Pharma on inhaled GLP-1 therapy - investing.com
MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management - The Manila Times
MannKind and Rose Pharma Enter Worldwide Collaboration to Develop Inhaled ROSE-010 Technosphere for Weight Management - Quiver Quantitative
MannKind and Rose Pharma Inc Enter Licensing and - GlobeNewswire
MannKind to Present at Upcoming Investor Conferences - The Manila Times
MannKind (MNKD) Could Be 48% Undervalued Following Its Afrezza And Pipeline Narrative - Yahoo Finance
MannKind Corp (MNKD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - tradingkey.com
MannKind Corporation Submits Prospectus Supplement with Legal Opinion on Common Stock Offering - Kalkine Media
MannKind (NASDAQ: MNKD) resale taps $0.01 warrant shares - Stock Titan
MannKind files legal opinion for common stock offering under shelf registration - TradingView
MannKind (MNKD) Quarterly Update: Profit Per Share Falls Below Its Benchmark for This Review; Shares After the Report: The Stock Gains 4.36% in Latest TradingEarnings Expansion Phase - careplusvn.com
How MannKind’s (MNKD) Rising Revenue but Renewed Losses Could Reshape Its Growth Investment Story - simplywall.st
Rubric Capital discloses 5.83% MannKind Corporation (MNKD) stake - Stock Titan
Research Analysts Set Expectations for MannKind Q3 Earnings - MarketBeat
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):